Corbus Pharmaceuticals Reports Director Departure and Shareholder Votes

Corbus Pharmaceuticals Holdings Inc. (CRBP) reported the departure of a director and detailed voting outcomes from its 2025 annual shareholder meeting in a Form 8-K filed with the SEC on May 14, 2026.

The filing covers four items: departure or election of directors or principal officers, submission of matters to a vote of security holders, Regulation FD disclosure, and exhibits. Item 5.02 addresses the board change while Item 5.07 reports the precise vote tallies on each proposal placed before shareholders.

Corbus has one class of common stock outstanding. The shareholder meeting affected all record holders of that stock. The company did not disclose the exact number of shares voted or the identity of the departing director in the provided summary data.

The director departure removes one member from the board effective on or before the May 14, 2026 filing date. The prior board size is not stated in the filing. The new board composition takes effect immediately upon the departure. Shareholder votes ratified or rejected the company’s nominated slate and any other proposals under Item 5.07; specific percentages or for/against counts are contained in the exhibits filed with the 8-K.

Downstream, the company must update its board roster in future proxy statements and Section 16 filings for any affected insiders. If the departing director held a committee chair or membership, those assignments must be reassigned and disclosed in the next quarterly report or on Form 8-K.

The Regulation FD item indicates the company furnished the information to the public, satisfying fair-disclosure obligations and starting the clock on any related quiet-period or blackout rules. Standard Form 8-K deadlines were met by the same-day filing.

This marks the latest board-level change reported by the clinical-stage pharmaceutical company. Corbus last filed an 8-K addressing executive compensation and equity plans in 2025; the current disclosure follows the routine annual-meeting cycle required for all public companies under SEC rules.